The natural history of ovarian cancer continues to be characterized by late-stage
presentation, metastatic bulky disease burden and stagnant mortality statistics, despite …

The treatment of ovarian cancer is set to undergo rapid changes, as strategies incorporating
molecular targeted therapies begin to take shape. These are based on a better appreciation …

OBJECTIVES: Sorafenib, an oral multikinase inhibitor of the VEGFR/PDGFR/Raf/MEK/ERK
pathway, has shown potential activity in patients with recurrent ovarian cancer (OC). One …

Ovarian cancer represents the most lethal tumor type among malignancies of the female
reproductive system. Overall survival rates remain low. In this study, we identify the serine …

Ovarian cancer is the leading cause of death in women with gynecological cancer. Most
patients are diagnosed at an advanced stage with a poor prognosis. Currently, surgical …

Introduction: Epithelial ovarian cancer (EOC) is the leading cause of gynaecologic cancer
death. Although in some cases initial treatment is effective, most of the women diagnosed …

Ten topics were chosen among major clinical research achievements in gynecologic
oncology in 2012. For ovarian cancer, comprehensive review of the history of bevacizumab …

The epidermal growth-factor receptor (EGFR) is overexpressed in the majority of epithelial
ovarian cancers and promotes cell proliferation, migration and invasion, and angiogenesis …

Advanced epithelial ovarian cancer, cancer of the fallopian tube and primary peritoneal
cancer have a poor prognosis and a high rate of disease recurrence following primary …

Introduction: Epithelial ovarian cancer (EOC) is the second most common gynecologic
malignancy and the leading cause of death from gynecologic cancer in the USA. EOC is an …